Doseology Sciences Expands Portfolio with Feed That Brain Acquisition

Doseology Expands Its Portfolio Through Strategic Acquisition

In a significant move for the biotech industry, Doseology Sciences Inc. (CSE: MOOD), renowned for its innovative approach to precision-formulated oral stimulants, has announced the completion of its acquisition of the 'Feed That Brain' division, previously operated by Joseph Mimran Associates Inc. This acquisition is expected to enhance Doseology's product offerings and further establish its leadership in cognitive enhancement products.

This acquisition, initially announced on August 19, 2025, has now been officially finalized. As part of the agreement, Doseology issued 175,000 common shares at a deemed price of $1.00 per share to the vendor, satisfying the first payment of the asset purchase agreement. It's important to note that the shares are subject to a four-month hold period, as mandated by Canadian Securities Laws.

About Doseology Sciences
Doseology is on the cutting edge of biotechnology, focusing on engineering oral stimulants specifically designed to improve energy, focus, and cognitive performance. The company's commitment to scientific research and advanced delivery technologies reflects its goal of creating next-generation performance solutions that empower individuals to reach their peak potential. By incorporating 'Feed That Brain' into its portfolio, Doseology aims to further innovate and offer health-conscious consumers precise formulations that enhance mental acuity.

Through this acquisition, Doseology is not only expanding its product line but also strengthening its market position. The 'Feed That Brain' division, known for its effective cognitive supplements, aligns seamlessly with Doseology’s vision of delivering health-optimized solutions. This integration is expected to create synergies that will benefit both companies as Doseology leverages innovative research and development strategies.

As shared by Chris Jackson, CEO of Doseology Sciences, the acquisition marks an exciting chapter for the company as it continues to explore new horizons in biotechnological advancements. This added division represents not just a product acquisition, but a partnership that will push the boundaries of cognitive health and performance.

Future Outlook

While Doseology celebrates this accomplishment, the company is mindful of the challenges ahead. It emphasizes the importance of adapting to market dynamics and evolving consumer needs. The forward-looking statements provided in their announcements serve as a reminder of the risks and uncertainties that could impact future results. Nevertheless, Doseology remains confident in its strategic direction and the foundation being built through such acquisitions.

Over the coming months, investors and consumers alike will be watching closely as Doseology implements its expansion strategy and develops new, cutting-edge products. The company encourages stakeholders to keep updated through its official website at doseology.com and its future press releases.

In conclusion, with the acquisition of 'Feed That Brain,' Doseology underscores its commitment to pushing the envelope in cognitive health through scientific innovation. As the company embarks on this journey, it not only aims to strengthen its brand but also hopes to significantly impact the lives of those looking to enhance their cognitive performance optimally.